You are here

  • Home
  • Archive
  • Volume 33, Issue 10
  • Correction: A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovaria…

Article Text

Article menu

Download PDFPDF

Correction
Correction: A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer
Free

http://dx.doi.org/10.1136/ijgc-2023-004812corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Holloway RW, Thaker P, Mendivil AA, et al. A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer Int J Gynecol Cancer 2023; 33: 1458-1463.

    This article has been corrected since it was first published, to correct author name ‘Ramez Eskander’.